Short-, medium- and long-term outcome in patients with Idiopathic Inflammatory Myopathy

• Principal Investigator:

  Katalin Danko, Andrea Ponyi, Debrecen, Tamas Constantin, Budapest, Hungary

• Study Design:

  Natural History (Survival and Clinical Course) and Functional Outcome Retrospective, Cross-sectional and Prospective Study

• Types & Number of IIM Studied:

  Polymyositis, Dermatomyositis, Overlap myositis, Juvenile dermatomyositis, cancer-associated myositis (N = 105)

• Entry Criteria:

  Probable or definite Bohan and Peter criteria for idiopathic inflammatory myopathy

• IMACS Core Set Measures Included:

  Physician and Patient Global Activity Assessment, Manual Muscle Testing, Childhood Myositis Assessment Scale, Health Assessment Questionnaire, Enzymes, Myositis Disease Activity Assessment Tool; Myositis Damage Index, Health Related Quality of Life by SF-36 and Child Health Questionnaire

• Other Measures Included:

  MHC-typing, Myositis specific autoantibodies, Extra-muscular involvement, Work status, Development of other illnesses, Development of therapy- and disease-related complications

• Primary Outcome:

  Death, Relapses; IMACS Definitions of Improvement

• Study Duration:

  Retrospective and Cross-sectional Study: Completed (2003) Prospective Study: Ongoing and Open (2003-2008)

• Funding:

  Hungarian Scientific Foundation (T046931), Hungarian Health Council (11 CO 24/0004 3/20)

• Contact:

  Dr. Katalin Danko, email: danko@iiibel.dote.hu, Dr. Andrea Ponyi, email: ponyi@iiibel.dote.hu, Phone: 36--52- 414-969, OR Dr. Tamas Constantin, E-mail: ctamas@gyer2.sote.hu, Phone: +36-1-215-1380

Return to Natural History Studies listing